SABCS 2023

YiR in EBC #2: De-escalating therapy in locoregional recurrence, adjuant therapy with CDK4/6i and new insights in pregnancy/fertility preservation after EBC

YiR in EBC #1: New data in HER2+ and Immunotherapy in HR+ and TNBC

YiR in ABC #1: Exciting new data for first line mTNBC, progress in HER2+ therapy and new data on triple-positive disease

YiR in ABC #2: New data on treatment in metastatic HR+ breast cancer - CDK4/6i and beyond

YiR in ABC #3: Exciting new data on ADCs in HR+ breast cancer

cTDNA analyses in monarchE

CheckMate7FL - Biomarker

Hope with CPI for luminal breast cancer

An enrichment of therapy options in the endocrine treatment of HR+ breast cancer

Prediction of pCR in KEYNOTE-756

SABCS23 highlights in early breast cancer

KEYNOTE-756 - Subgroup analysis

Final iDSF analysis in NATALEE

ADAPTcycle - endocrine response

Change in the standard of follow-up care?

KATHERINE: OS improvement in HER2+ eBC

T-DM1 in post-neoadjuvant therapy now also with OS-benefit

Immunotherapy for early TNBC must be neoadjuvant

Pregnancy after BC is safe - also in germline BRCA+ pts

Pregnancy despite endocrine therapy in HR+ breast cancer

Importance of the onco-fertility discussion

Anthtracyclines in EBC: to give or not to give?

Análisis de cTDNA en monarchE

KATHERINE : amélioration de la survie globale dans le cancer du sein précoce HER2+

SABCS23 evidenzia il cancro al mammario in fase precoce

Importância da discussão sobre onco-fertilidade

Gravidanza dopo la diagnosi di carcinoma mammario è sicura anche nelle pazienti gBRCA+

OS benefit with fulvestrant/letrozole + palbocilib is similar to othter CDK4/6i in first line

Is OS important?

Does abemciclib lead to improved OS survival in the 1st line setting?

Long follow-up of CDK4/6i

T-DXd + endocrine therapy interesting for HR+ HER2low mBC

Fulvestrant + futibatinib interesting for FGFR1 amplifications

Letrozole + palbo as effective as fulvestrant + palbo

Capiversatib + Palbociclib + Fulvestrant in HR+ HER2- mBC

MONARCH 3 shows clinically relevant OS-benefit without statistical significance

Final OS analysis in MONARCH 3

Dato-Dxd achieves PFS

SABCS23 highlights in metastatic breast cancer

Promising data for the PIK3CA-inhibitor inavolisib

PIK3CA-inhibitor: positive results in Phase III

Tucatinib + T-DM1: Possible role in the contemporary landscape?

Tucatinib + T-DM1 interesting for specific patients

Effective, chemo-free combination for triple-positive MBC

New potential backbone for tucatinib in mHER2+ BC

Efficacy of tucatinib confirmed, but unclear for which patients still relevant

Avelumab appears to be effective in HER2+ mBC

KEYLYNK-009: Pembrolizumab + olaparib a well-tolerated combination

Axillary radiotherapy can be omitted in T3N1 BC pts

Rethinking management of the axilla

Physical acitivity improves QoL in advanced BC

Isolated tumor cells in the sentinel lymph node - does it have to be the axilla dissection?

Positive sentinel lymph node after mastectomy

Metastatic patients can and must exercise

Axillary surgery de-escalation

Low-dose olanzapine more favorable in the prophylaxis of CINV

Poster insights: PO4-01-10 ADAPTcycle

L'attività fisica migliora la qualità di vita nel cancro al seno avanzato

Desescalada de cirugía axilar

Tucatinib + T-DM1: Possibile un ruolo nello scenario attuale?

Tukatynib skuteczny, ale czy umiemy określić jego miejsce?

La supervivencia obtenida con palbociclib y letrozol/fulvestrant es similar a la de otros CDK4/6i en primera línea

Capiversatib + Palbociclib + Fulvestrant nel carcinoma mammario HR+ HER2-

Duże zmiany w leczeniu pachy

Capiversatib + Palbociclib + Fulvestrant dans le cancer du sein HR+ HER2-

Dato-Dxd consigue PFS

La radioterapia ascellare può essere omessa nelle pazienti con carcinoma mammario T3N1

Inhibiteur de PIK3CA: résultats positifs en phase III

SABCS23 evidenzia nel cancro al mammario metastatico

New and good therapy options for HER2+ patients

Immunotherapy and combination therapies for HR+/HER2- and TNBC

No significant OS - but what is the impact on clincial practice?!

Good balance between benefits and side effect - but not guideline changing, yet?!

DE-escalation of the axillary interverntion after neoadjuvant therapy

Pregnancy is safe after endocrine therapy

De-escalation of radiotherapy after neoadjuvant therapy

PI3K inihbitor Inavolisib shows improved PFS - one step closer to a new era?!

OS and final iDFS data - confirming data but risk and benefits must be balanced

Final iDFS data - is everything clear yet?